glp-1 class drugs Costs Explained: Managing Coverage Challenges The Impact of GLP-1 Receptor

Therapy in the early stage: incretins

Anti-inflammation and Anti-oxidation: the Key to unlocking the Cardiovascular potential of SGLT2 inhibitors and GLP1 receptor agonists

doi: 10.1210/en.2003-0143

At the same time, the desire to breastfeed is equally valid

Although GLP-1RAs can reduce body weight by 15%25% in controlled settings, real-world adherence is limited, and nearly 70% of patients experience weight regain after discontinuation, raising the risk of long-term pharmacological dependence ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications